CN109843292A - 治疗骨疾病的PPARγ激动剂 - Google Patents

治疗骨疾病的PPARγ激动剂 Download PDF

Info

Publication number
CN109843292A
CN109843292A CN201780063392.8A CN201780063392A CN109843292A CN 109843292 A CN109843292 A CN 109843292A CN 201780063392 A CN201780063392 A CN 201780063392A CN 109843292 A CN109843292 A CN 109843292A
Authority
CN
China
Prior art keywords
compound
int131
effective amount
therapeutically effective
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780063392.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·兰费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellin Therapeutic Co Ltd
Original Assignee
Intellin Therapeutic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellin Therapeutic Co Ltd filed Critical Intellin Therapeutic Co Ltd
Publication of CN109843292A publication Critical patent/CN109843292A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
CN201780063392.8A 2016-08-18 2017-08-18 治疗骨疾病的PPARγ激动剂 Pending CN109843292A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
US62/376,732 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Publications (1)

Publication Number Publication Date
CN109843292A true CN109843292A (zh) 2019-06-04

Family

ID=61197122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780063392.8A Pending CN109843292A (zh) 2016-08-18 2017-08-18 治疗骨疾病的PPARγ激动剂

Country Status (11)

Country Link
US (1) US20190167660A1 (https=)
EP (1) EP3500269A4 (https=)
JP (2) JP2019524889A (https=)
KR (1) KR20190065252A (https=)
CN (1) CN109843292A (https=)
AU (1) AU2017313842A1 (https=)
BR (1) BR112019003133A2 (https=)
CA (1) CA3033971A1 (https=)
EA (1) EA201990513A1 (https=)
SG (2) SG10202101500WA (https=)
WO (1) WO2018035449A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440383A (zh) * 2000-04-28 2003-09-03 三共株式会社 PPARγ调制剂
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
CN1886134A (zh) * 2003-10-03 2006-12-27 安进公司 有效的抗糖尿病化合物的盐和多晶型物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
ES2785317T3 (es) * 2014-10-10 2020-10-06 Liminal Biosciences Ltd Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440383A (zh) * 2000-04-28 2003-09-03 三共株式会社 PPARγ调制剂
CN1886134A (zh) * 2003-10-03 2006-12-27 安进公司 有效的抗糖尿病化合物的盐和多晶型物
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, DAE HO等: "Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice", 《AMERICAN JOURNAL OF PHYSIOLOGY》 *

Also Published As

Publication number Publication date
KR20190065252A (ko) 2019-06-11
EP3500269A4 (en) 2020-04-15
SG10202101500WA (en) 2021-03-30
SG11201901328VA (en) 2019-03-28
EA201990513A1 (ru) 2019-08-30
US20190167660A1 (en) 2019-06-06
WO2018035449A1 (en) 2018-02-22
BR112019003133A2 (pt) 2019-05-21
AU2017313842A1 (en) 2019-03-07
JP2022116294A (ja) 2022-08-09
CA3033971A1 (en) 2018-02-22
JP2019524889A (ja) 2019-09-05
EP3500269A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
Gehrke et al. Long-term consequences of osteoporosis therapy with bisphosphonates
Reid Efficacy, effectiveness and side effects of medications used to prevent fractures
Henriksen et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2
Murphy et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
Azria et al. 25 years of salmon calcitonin: from synthesis to therapeutic use
Ijuin et al. Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: a case study
Eller-Vainicher et al. Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia
JP2011241221A (ja) ビタミンｄ誘導体の前用量投与によってアレンドロネート等のビスフォスフォネートの生体利用効率を高める方法
Hough et al. The safety of osteoporosis medication
Martínez-Morillo et al. Premenopausal osteoporosis: how to treat?
Gu et al. Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: a randomized, double-blind, placebo-controlled, multicenter phase III study
CN109843292A (zh) 治疗骨疾病的PPARγ激动剂
Kourtis et al. Understanding and managing fracture risk in patients with cancer: a literature review
Ali et al. Effective strategies for pregnancy and lactation-associated osteoporosis: Teriparatide use in focus
Shomali et al. Hypercalcemia in a woman with hypoparathyroidism associated with increased parathyroid hormone-related protein during lactation
Kucherov et al. Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women
Farías et al. Relative bioavailability between two teriparatide formulations in healthy volunteers
Rodrigo Introductory chapter: Osteoporosis overview
El Miedany Geroscience and management of osteoporosis in older adults
Tansey et al. Pituitary production of prolactin and prolactin-suppressing drugs
Goshima et al. Effective management of pregnancy-and lactation-associated osteoporosis using romosozumab: a clinical case report
Rose et al. Endocrine complications of cancer therapy
Rizvi Some clues and pitfalls in the diagnosis of acromegaly
Leung et al. Neuroendocrine complications of cancer therapy
Wijekoon et al. Efficacy and safety of once weekly thyroxine versus daily thyroxine as maintenance therapy of hypothyroidism: a randomised controlled clinical trial

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190604